These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20215481)

  • 21. Successful rechallenge after ixabepilone-induced radiation recall dermatitis using an alternative dosing strategy.
    Ford JN; Newton M; Jordan C; Abraham J
    J Oncol Pharm Pract; 2013 Mar; 19(1):89-92. PubMed ID: 22323422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with epothilones in patients with breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes.
    Murphy CG; Seidman AD
    Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S58-65. PubMed ID: 19596644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epothilones in the treatment of cancer.
    Larkin JM; Kaye SB
    Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.
    Denduluri N; Lee JJ; Walshe J; Berman AW; Vatas U; Chow CK; Steinberg SM; Cox MC; Low JA; Swain SM
    Invest New Drugs; 2007 Feb; 25(1):63-7. PubMed ID: 16933153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones.
    Pronzato P
    Drugs; 2008; 68(2):139-46. PubMed ID: 18197722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?
    Tan AR; Toppmeyer DL
    Clin Cancer Res; 2008 Nov; 14(21):6725-9. PubMed ID: 18980963
    [No Abstract]   [Full Text] [Related]  

  • 28. The epothilones: how pharmacology relates to clinical utility.
    Michaud LB
    Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
    Rivera E
    Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ixabepilone: new drug. Similar to taxanes, but no better.
    Prescrire Int; 2009 Aug; 18(102):160. PubMed ID: 19743574
    [No Abstract]   [Full Text] [Related]  

  • 32. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ixabepilone.
    Stein A
    Clin J Oncol Nurs; 2010 Feb; 14(1):65-71. PubMed ID: 20118028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ixabepilone: a new active chemotherapy in the treatment of breast cancer.
    Villanueva C; Vuillemin AT; Demarchi M; Bazan F; Chaigneau L; Pivot X
    Womens Health (Lond); 2009 Mar; 5(2):115-21. PubMed ID: 19245349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.
    De Luca A; D'Alessio A; Maiello MR; Gallo M; Chicchinelli N; Pergameno M; Piccirilli MS; Normanno N
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1177-85. PubMed ID: 26073581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
    Cigler T; Vahdat L
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of ixabepilone for treating metastatic breast cancer.
    Li J; Ren J; Sun W
    Breast Cancer; 2017 Mar; 24(2):171-179. PubMed ID: 27491426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
    Perez EA; Patel T; Moreno-Aspitia A
    Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
    Villanueva C; Dufresne A; Pivot X; Viel E
    Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
    Baselga J; Zambetti M; Llombart-Cussac A; Manikhas G; Kubista E; Steger GG; Makhson A; Tjulandin S; Ludwig H; Verrill M; Ciruelos E; Egyhazi S; Xu LA; Zerba KE; Lee H; Clark E; Galbraith S
    J Clin Oncol; 2009 Feb; 27(4):526-34. PubMed ID: 19075286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.